<DOC>
	<DOCNO>NCT00866281</DOCNO>
	<brief_summary>This phase I/II pediatric dose-ranging study evaluate safety , tolerability , clinical response , pharmacokinetics pharmacodynamics midostaurin patient &lt; 18 year age relapse refractory acute leukemia may benefit administration midostaurin , include MLL-rearranged ALL FLT3 positive AML .</brief_summary>
	<brief_title>A Study Safety Preliminary Efficacy Oral Midostaurin ( PKC412 ) Relapsed Refractory Pediatric Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Mixedlineage leukemia ( MLL ) gene rearrange Acute Lymphoblastic Leukemia ( ALL ) , respond treatment relapse prior treatment ; FLT3 mutate Acute Myeloid Leukemia ( AML ) respond second treatment relapse 2 prior treatment Normal organ function , chest xray Expected survival great 8 week Can care personal need perform least minimum activity Patients symptomatic leukemic central nervous system involvement isolate extramedullary leukemia Patients must receive treatment leukemia within predefined time period , 72 hour medication , 2 month transplant Patients heart function normal Patients HIV hepatitis Patients another severe disease medical condition besides leukemia Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>midostaurin</keyword>
	<keyword>PKC412</keyword>
	<keyword>Pediatric relapse refractory FLT3 positive Acute Myeloid Leukemia</keyword>
	<keyword>Pediatric relapse refractory Mixed-lineage leukemia gene rearrange Acute Lymphoblastic leukemia</keyword>
</DOC>